The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Open accessAbstract
OBJECTIVE: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders. METHODS: A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and selected movement disorders. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I-IV). RESULTS: The highest quality literature available for the respective indications was as follows: blepharospasm (two Class II studies); hemifacial spasm (one Class II and one Class III study); cervical dystonia (seven Class I studies); focal upper extremity dystonia (one Class I and three Class II studies); focal lower extremity dystonia (one Class II study); laryngeal dystonia (one Class I study); motor tics (one Class II study); and upper extremity essential tremor (two Class II studies). RECOMMENDATIONS: Botulinum neurotoxin should be offered as a treatment option for the treatment of cervical dystonia (Level A), may be offered for blepharospasm, focal upper extremity dystonia, adductor laryngeal dystonia, and upper extremity essential tremor (Level B), and may be considered for hemifacial spasm, focal lower limb dystonia, and motor tics (Level C). While clinicians' practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jankovic, J., Schwartz, K., Clemence, W., Aswad, A., & Mordaunt, J. (1996) · Movement Disorders · doi:10.1002/mds.870110306 · Cited by 235
Self-citation
Cited by
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012658 · Cited by 768
Gulati, S., & Sondhi, V. (2018) · The Indian Journal of Pediatrics · doi:10.1007/s12098-017-2475-1 · Cited by 733
Treatment of patients with essential tremor
Deuschl, G., Raethjen, J., Hellriegel, H., & Elble, R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70322-7 · Cited by 428
The non-motor syndrome of primary dystonia: clinical and pathophysiological implications
Stamelou, M., Edwards, M. J., Hallett, M., & Bhatia, K. P. (2012) · Brain · doi:10.1093/brain/awr224 · Cited by 299
Self-citationThe updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy
Heinen, F., Desloovere, K., Schroeder, A. S., Berweck, S., Borggraefe, I., van Campenhout, A., Andersen, G. L., Aydin, R., Becher, J. G., Bernert, G., et al. (2010) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2009.09.005 · Cited by 296
Metadata
- Authors
- Simpson, D. M., Blitzer, A., Brashear, A., Comella, C., Dubinsky, R., Hallett, M., Jankovic, J., Karp, B., Ludlow, C. L., Miyasaki, J. M., Naumann, M., & So, Y.
- Venue
- Neurology
- Published
- 2008-05-06
- Volume
- 70
- Issue
- 19
- Pages
- 1699-1706
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2795831496
- Cited by
- 618
- References
- 1
- FWCI
- 34.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. https://app.cochat.ai/papers/10.1212/01.wnl.0000311389.26145.95
- The paper
- Simpson, D. M., Blitzer, A., Brashear, A., Comella, C., Dubinsky, R., Hallett, M., Jankovic, J., Karp, B., Ludlow, C. L., Miyasaki, J. M., Naumann, M., & So, Y. (2008). Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. https://doi.org/10.1212/01.wnl.0000311389.26145.95
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.